Recent Updates
Recently added Catalysts
RDY Neutral Sentiment Score: 45/100

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad - 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.c

Key Takeaway: Dr. Reddy's Laboratories Ltd. has disclosed that its subsidiary, Aurigene Oncology Limited, has received a tax demand order from the GST Appellate Authority. This order includes a penalty totaling Rs.3,46,998 due to alleged violations related to output tax and input tax credit. The appeal against this tax demand has been dismissed, although the company has indicated potential plans to file further appeals. Despite the penalty, the company assessed that there is no material impact on its financials or operations.

Market Sentiment Analysis

CONCERNS & RISKS

  • Aurigene is facing a tax demand which includes an interest and penalty.
  • The appeal filed against the tax demand has been dismissed.
  • The authority cited short payment of output tax and excess claims of input tax credit as reasons for the order.

Full Press Release Details

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
This is to inform that the Aurigene Oncology Limited (formerly known as Aurigene Discovery Technologies Limited) ("Aurigene"), a wholly owned subsidiary of the Company, has received an order from GST Appellate Authority towards tax demand including interest and penalty. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:
Name of the authority Office of the Appellate Joint Commissioner of State Tax, Hyderabad Rural Division, Hyderabad, 5th Floor, C.T.Complex, Nampally, Hyderabad.
Nature and details of the action(s) taken, initiated or order(s) passed Aurigene had filed an appeal with appellate authority dated 16.05.2025 and the appeal stands dismissed seeking demand including interest and penalty under SGST/ CGST/ IGST Act, 2017.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority Order dated 25.11.2025 was received by the Company on 25.11.2025 via an email.
Details of the violation(s)/ contravention(s) committed or alleged to be committed The authority has passed the order on the contention that short payment of output tax and excess claim of input tax credit.
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible The above order levies a penalty of Rs.3,46,998/-. Based on our evaluation, there is no material impact on the financials, operations, or other activities of the Company.
The Company will evaluate filing necessary appeal with the appellate authority in this regard.
This is for your information and records.
For Dr. Reddy's Laboratories Limited
Company Secretary, Compliance Officer & Head-CSR

Frequently Asked Questions

What subsidiary of Dr. Reddy's Laboratories received a tax order?

Aurigene Oncology Limited, a wholly owned subsidiary, received the tax order.

What was the outcome of Aurigene's appeal to the appellate authority?

Aurigene's appeal filed on 16.05.2025 was dismissed by the appellate authority.

What penalty did Aurigene receive from the tax authority?

Aurigene was levied a penalty of Rs.3,46,998 for tax violations.

Are the financial operations of Dr. Reddy's impacted by the penalty?

The company assessed that the penalty will not materially impact its financials.

What steps will the company take following the tax order?

The company is considering filing an appeal with the appellate authority.

Last updated: Nov 26, 2025